CombiMatrix to Present New Data from a Large-Scale Analysis of Genomic Abnormalities Impacting Multiple Stages of Human Growt...
October 20 2017 - 6:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular
diagnostics company specializing in DNA-based reproductive health
and pediatric testing services, announces the presentation of new
data from a large-scale, first-of-its kind study providing a
comprehensive assessment of chromosomal imbalances and their
adverse impact upon human growth and development from conception to
childhood. Results from nearly 32,000 samples analyzed in this
study indicate that genomic alterations decrease in frequency and
severity from conception through development into childhood.
Trilochan Sahoo, M.D., FACMG, CombiMatrix Vice President of
Clinical Affairs and Director of Cytogenetics, will discuss these
results today at the American Society of Human Genetics Annual
Meeting (ASHG) in Orlando, Fla.
This study is aimed at exploring and cataloging
the frequency, severity and complex evolution of genomic
abnormalities with adverse effects on human conception, pregnancy
and childhood growth and development. Data was obtained from
CombiMatrix’s exclusive data collected over a multi-year
period. An abstract of the study, “Large-scale cytogenomic
analysis of samples from conception to childhood: a comprehensive
assessment of the landscape of unbalanced genomic abnormalities,”
is posted at
http://combimatrix.com/providers/educational-references.
The abstract reviews outcomes from
preimplantation genetic screening (PGS) of 6,883 embryos and
chromosomal microarray analysis testing of 12,324 pregnancy loss
samples, 4,176 prenatal samples, 1,564 neonatal samples and 7,047
pediatric samples. The study showed a spectrum of unbalanced
genomic abnormalities detected in each sample type. Key
findings include:
- Embryo or early pregnancy loss samples showed the highest
abnormality rates and a predictable correlation between the
severity of chromosomal abnormalities, primarily aneuploidies, with
unsuccessful implantation or progression to viable
pregnancy.
- Prenatal and neonatal samples showed that the frequency of
significant genomic alterations correlated with the incidence of
significant physical and developmental abnormalities, but were not
necessarily incompatible with life.
- Pediatric samples were predominantly deletions and duplications
rather than aneuploidy and had less drastic adverse effects.
“This is the first study to provide a
comprehensive overview of the nature and frequency of cytogenomic
abnormalities with adverse effects from the earliest
post-conception developmental stages (i.e., embryos) through
pregnancy and into childhood,” said Dr. Sahoo. “Analysis of
this larger sample set validates our previous findings that showed
an interesting pattern elucidating genomic alterations of
decreasing severity as human growth progresses these developmental
stages. This opens a new window into the errors and corrective
mechanisms at play at a cellular level during various stages of
human
development.”
“These results support the importance of genomic testing for
different abnormalities that may occur at distinct development
stages,” said Mark McDonough, CombiMatrix President and CEO. “We
now have even more compelling evidence of the importance of the
genetic information produced from this testing from preconception
through early childhood. It is our goal to provide useful and
timely information that can help physicians and their patients make
important health decisions.”
About CombiMatrix Corporation
CombiMatrix Corporation provides sophisticated
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic diagnostics and screening,
prenatal diagnosis, miscarriage analysis and pediatric
developmental disorders, offering DNA-based testing for the
detection of genetic abnormalities beyond what can be identified
through traditional methodologies. Our testing focuses on advanced
technologies, including single nucleotide polymorphism chromosomal
microarray analysis, next generation sequencing, fluorescent in
situ hybridization and high resolution karyotyping. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling (800) 710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," "outlook," "reach," similar
expressions, and variations or negatives of these words and
include, but are not limited to, statements regarding projected
results of operations, including projected cash flow-positive
operating results, management's future business, operational and
strategic plans, recruiting efforts and test menu expansion. These
forward-looking statements are not guarantees of future results and
are subject to risks, uncertainties and assumptions that could
cause our actual results to differ materially and adversely from
those expressed in any forward-looking statement. The risks and
uncertainties referred to above include, but are not limited to:
our ability to grow revenue and improve gross margin; delays in
achieving and maintaining cash flow-positive operating results; the
risk that operating expenses are not reduced or increase; the risk
that test volumes and reimbursements level off or decline; the risk
that payors decide to not cover our tests or to reduce the amounts
they are willing to pay for our tests; the risk that we will not be
able to grow our business as quickly as we need to; the inability
to raise capital; the loss of members of our sales force; our
ability to successfully expand the base of our customers, add to
the menu of our diagnostic tests, develop and introduce new tests
and related reports, expand and improve our current suite of
services, optimize the reimbursements received for our microarray
testing services, and increase operating margins by improving
overall productivity and expanding sales volumes; our ability to
successfully accelerate sales, steadily increase the size of our
customer rosters in all of our genetic testing markets; our ability
to attract and retain a qualified sales force in wider geographies;
our ability to ramp production from our sales; rapid technological
change in our markets; changes in demand for our future services;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further information
on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update publicly
any forward-looking statements for any reason, except as required
by law.
Company Contact: Mark
McDonough President & CEO,
CombiMatrix Corporation(949) 753-0624
Investor
Contact:
LHA Investor Relations
Jody Cain (310)
691-7100jcain@lhai.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Sep 2023 to Sep 2024